Atomoxetine + placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
ADHD
Conditions
ADHD, Comorbid Alcohol Abuse
Trial Timeline
Aug 1, 2004 → Jan 1, 2006
NCT ID
NCT00190957About Atomoxetine + placebo
Atomoxetine + placebo is a approved stage product being developed by Eli Lilly for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00190957. Target conditions include ADHD, Comorbid Alcohol Abuse.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00962104 | Phase 3 | Completed |
| NCT00716274 | Approved | Completed |
| NCT00607919 | Approved | Completed |
| NCT00546910 | Approved | Completed |
| NCT00617201 | Phase 2 | Completed |
| NCT00406354 | Approved | Completed |
| NCT00380692 | Approved | Completed |
| NCT00260533 | Phase 2/3 | Completed |
| NCT00191542 | Phase 3 | Completed |
| NCT00191295 | Phase 2/3 | Completed |
| NCT00190957 | Approved | Completed |
| NCT00386581 | Phase 3 | Completed |
| NCT00611533 | Pre-clinical | Completed |
Competing Products
20 competing products in ADHD